The long-term goal of this project is to develop better therapies for acute influenza virus-induced respiratory disease and asthma. Influenza virus (an NIAID Category C pathogen) causes infection that is major public health problem, resulting in about 40,000 deaths and more than 200,000 hospitalizations annually in the US, with a total cost of over $10 billion/year. The 2009 swine flu pandemic demonstrated that patients with asthma are at particularly high risk for developing severe influenza infection, associated with hospitalization and death. As the numbers reflect, current therapies for acute influenza-induced respiratory disease are not fully effective, in part because the host-influenza interactions resulting in, and mechanisms by which influenza infection causes, acute respiratory disease and asthma are not fully understood.
In Specific Aim 1 we will examine a specific intervention that targets a novel innate lymphoid cell type in the lungs, called natural helper cells or nuocytes. We recently showed that natural helper cells are specifically activated during influenza infection and are required for influenza-induced asthma in mice. We will use a unique experimental model of influenza-induced airway inflammation and airway hyperreactivity (AHR) (a cardinal feature of asthma) that develops independently of Th2 cells and adaptive immunity, and which may reflect human influenza-induced respiratory disease and asthma. The response is initiated when influenza infects alveolar macrophages, leading to pyroptosis and release of IL-33, which then activates natural helper cells to produce IL-13, which in turn mediates acute AHR. We will demonstrate that by targeting natural helper cells with c-Kit kinase inhibitors (imatinib or masitinib), influenza-induced airway pathology can be abolished. Such therapy may be much more effective than high dose corticosteroids, commonly used in patients with influenza-induced asthma.
In Specific Aim 2 we will further refine the approach of targeting natural helper cells during influenza infection, and examine the interaction of influenza with host cells resulting in the production of IL-33, IL-25, and TSLP. All three of these cytokines potently activate natural helper cells, inducing them to produce IL-13. These studies will define host-influenza interactions and the biology of natural helper cells in this complex innate pathway, described only one year ago. Understanding the many components of this pathway is critical to provide key insights into how c-Kit kinase inhibitors fit into this pathway to reduce natural helper cell activity and influenza-induced asthma. These studies will focus on developing a novel therapeutic for acute, influenza-induced respiratory disease and asthma, which are serious, common clinical problems. The proposed therapeutic will target a host cell type activated by influenza and required for its pathogenesis. Moreover, study of this therapy will extend our fundamental understanding of mucosal immune responses.

Public Health Relevance

Influenza virus infection is a serious worldwide health threat that can result in hospitalization and serious respiratory disease in young children, the elderly, pregnant women and in particular patients with asthma who constitute nearly 10% of the general population in the US. We propose to study a therapy specifically targeting a novel pathogenic pathway that leads to virus-induced respiratory disease and asthma involving a newly defined innate cell type, called natural helper cells.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-DDS-M)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Harvard University
United States
Zip Code
Clark, Margaret J; Miduturu, Chandra; Schmidt, Aaron G et al. (2016) GNF-2 Inhibits Dengue Virus by Targeting Abl Kinases and the Viral E Protein. Cell Chem Biol 23:443-52
Russo, Brian C; Stamm, Luisa M; Raaben, Matthijs et al. (2016) Intermediate filaments enable pathogen docking to trigger type 3 effector translocation. Nat Microbiol 1:16025
Kirienko, Daniel R; Revtovich, Alexey V; Kirienko, Natalia V (2016) A High-Content, Phenotypic Screen Identifies Fluorouridine as an Inhibitor of Pyoverdine Biosynthesis and Pseudomonas aeruginosa Virulence. mSphere 1:
Taylor, Travis J; Diaz, Fernando; Colgrove, Robert C et al. (2016) Production of immunogenic West Nile virus-like particles using a herpes simplex virus 1 recombinant vector. Virology 496:186-93
Chou, Yi-ying; Cuevas, Christian; Carocci, Margot et al. (2016) Identification and Characterization of a Novel Broad-Spectrum Virus Entry Inhibitor. J Virol 90:4494-510
Mellata, Melha; Mitchell, Natalie M; Schödel, Florian et al. (2016) Novel vaccine antigen combinations elicit protective immune responses against Escherichia coli sepsis. Vaccine 34:656-62
Helenius, Iiro Taneli; Nair, Aisha; Bittar, Humberto E Trejo et al. (2016) Focused Screening Identifies Evoxine as a Small Molecule That Counteracts CO2-Induced Immune Suppression. J Biomol Screen 21:363-71
Stone, Laura K; Baym, Michael; Lieberman, Tami D et al. (2016) Compounds that select against the tetracycline-resistance efflux pump. Nat Chem Biol 12:902-904
Balasubramanian, Anuradha; Manzano, Mark; Teramoto, Tadahisa et al. (2016) High-throughput screening for the identification of small-molecule inhibitors of the flaviviral protease. Antiviral Res 134:6-16
Vrentas, Catherine E; Moayeri, Mahtab; Keefer, Andrea B et al. (2016) A Diverse Set of Single-domain Antibodies (VHHs) against the Anthrax Toxin Lethal and Edema Factors Provides a Basis for Construction of a Bispecific Agent That Protects against Anthrax Infection. J Biol Chem 291:21596-21606

Showing the most recent 10 out of 401 publications